Cumberland gets second Acetadote patent

The U.S. Patent and Trademark Office recently granted Cumberland Pharmaceuticals a patent for a new formulation of its Acedatote treatment for acetaminophen overdose. The patent award, which is effective through 2025, may not be the end of this chapter of the story, though: Cumberland last year had to fight off a number off challenges to its IP rights.